Are you Dr. Manfredi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 14 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1275 York Ave
New York, NY 10021Phone+1 646-227-3813- Is this information wrong?
Summary
- Dr. Paolo Manfredi, MD is a neurologist in New York, New York. He is currently licensed to practice medicine in New York and Massachusetts.
Education & Training
- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Neurology, 1991 - 1993
- Stony Brook MedicineInternship, Transitional Year, 1990 - 1991
- Univ Genoa- Fac MedClass of 1987
- Massachusetts General HospitalFellowship, Pain Medicine
Certifications & Licensure
- NY State Medical License 1993 - 2025
- MA State Medical License 1994 - 1996
Publications & Presentations
PubMed
- 5 citationsEsmethadone-HCl (REL-1017): a promising rapid antidepressant.Maurizio Fava, Stephen M Stahl, Sara De Martin, Andrea Mattarei, Ezio Bettini, Stefano Comai, Andrea Alimonti, Francesco Bifari, Luca Pani, Franco Folli, Clotilde Guid...> ;European Archives of Psychiatry and Clinical Neuroscience. 2023 Oct 1
- 3 citationsSubanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder.Clotilde Guidetti, Giulia Serra, Luca Pani, Marco Pappagallo, Gino Maglio, Sara De Martin, Andrea Mattarei, Franco Folli, Paolo L Manfredi, Maurizio Fava> ;The Primary Care Companion for CNS Disorders. 2023 Feb 14
- 16 citationsREL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study.Sara De Martin, Daniela Gabbia, Franco Folli, Francesco Bifari, Paolo Fiorina, Nicola Ferri, Stephen M. Stahl, Charles E. Inturrisi, Marco Pappagallo, Sergio Traversa,...> ;Frontiers in Pharmacology. 2021 Apr 28
- Join now to see all
Press Mentions
- Novel Antidepressant Shows Promise as Add-on TherapyJanuary 6th, 2022
- Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in the American Journal of PsychiatryJanuary 5th, 2022
- Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in the American Journal of PsychiatryDecember 22nd, 2021
- Join now to see all